IgG4 but no IgG1 antibody production after intralymphatic immunotherapy with recombinant MAT‐Feld1 in human. Issue 9 (17th June 2016)

• Record Type: Journal Article
• Authors: Freiberger, S. N.; Zehnder, M.; Gafvelin, G.; Grönlund, H.; Kündig, T. M.; Johansen, P.
• Is Part Of: Allergy. Volume 71:Issue 9(2016:Sep.)
• Page Start: 1366
• Page End: 1370
• Publication Date: 2016-06-17
• Subjects: antibody subclasses -- cat allergy -- intralymphatic immunotherapy -- recombinant allergen; Allergy -- Periodicals; 616.97
• DOI: 10.1111/all.12946
• Languages: English
• ISSNs: 0105-4538

Abstract

Abstract: Allergy immunotherapy (AIT) mediates protection against allergen exposure in part due to allergen‐specific antibodies. While immunization typically stimulated IgG1 and IgG2, AIT is often associated with production of IgG4. Here, twenty cat dander‐sensitized patients were randomized to receive three injections of intralymphatic immunotherapy (ILIT) with MAT‐Feld1 adsorbed to aluminum hydroxide or just aluminum hydroxide (placebo) in a double‐blind setting (ClinicalTrials.gov NCT00718679). Whereas the clinical data, showing benefit of Mat‐Feld1 ILIT was published in 2012 (Senti et al., J Allergy Clin Immunol, vol 129(5):1290–1296), the current study investigated the cat allergen‐specific antibody responses. Blood was drawn prior to ILIT, as well as 1, 3, and 12 months after first ILIT. The sera were analyzed to characterize all IgG subclasses and IgE antibody responses. ILIT with MAT‐Feld1 elicited high levels of total IgG that were maintained for at least 12 months. Interestingly, a strong increase in IgG4 and some increase in IgG2 were observed throughout the study, while production of cat‐specific IgG1 and IgG3 was not stimulated by MAT‐Feld1 ILIT. The IgE levels remained constant.